Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472324 | 0.91 | RXFP1 (0.54) | RXFP1MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL7032494 | 0.89 | CLK1 (0.53) | RXFP1MAPTTP53POLB | |
| SCHEMBL6258474 | 0.89 | POLB (0.52) | RXFP1MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL7038057 | 0.89 | MAPT (0.49) | RXFP1MAPTTP53SMN1; SMN2TDP1 | |
| SCHEMBL7032109 | 0.89 | MAPT (0.54) | RXFP1MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL7036764 | 0.86 | TP53 (0.55) | RXFP1MAPTTP53SMN1; SMN2TDP1 | |
| SCHEMBL7037451 | 0.85 | TRPA1 (0.54) | RXFP1MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL6272722 | 0.84 | NR1H4 (0.51) | RXFP1MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL6736358 | 0.84 | TRPA1 (0.51) | RXFP1MAPTTP53 | |
| SCHEMBL7023804 | 0.84 | TRPA1 (0.54) | MAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | RXFP1 173/4885MAPT 4800/4885TP53 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.